Pablo Corral/LinkedIn
Nov 9, 2025, 01:51
Pablo Corral: A True Game Changer in Lipid Management
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”AHA 2025 | CORALreef Lipids Trial
A true game changer in lipid management.
Enliciditide (MK-0616) – the first oral PCSK9 inhibitor – achieved a 57% LDL-C reduction at week 24 and – 50% sustained at week 52 vs placebo (p<0.001).
- Phase 3 trial, 2,912 patients with ASCVD or at high risk, across 14 countries, with excellent safety profile.
- Takeaway: efficacy and safety comparable to injectable PCSK9 inhibitors — but in a once-daily oral tablet.
- A new era in PCSK9 inhibition and cardiovascular prevention.”
Stay updated with Hemostasis Today.
-
Jan 10, 2026, 15:15Stefan Gerner on Stroke Care and Subarachnoid Hemorrhage
-
Jan 10, 2026, 15:02Dr Manikanta Receives AHA Fellowship to Investigate Platelet-Dependent Nucleic Acid-Sensing Pathways
-
Jan 10, 2026, 14:40Last day at ASH25 from Riten Kumar
-
Jan 10, 2026, 08:56Shivanand Kumatagi Reflects on His Visit to Rela Hospital
-
Jan 10, 2026, 08:48Mitchell Elkind: Why Is The American Heart Association Holding a Brain Health Symposium?
-
Jan 10, 2026, 08:41Fiona Robinson Invites You to NBDF Webinar on Research Grants
-
Jan 10, 2026, 08:30Melissa Korn Takes Front Page Award for Her WSJ Piece on Experiencing a Pulmonary Embolism
-
Jan 10, 2026, 08:20Aymar Akilimali on Malaria in the Democratic Republic of Congo
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council